Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649)

被引：0
|
作者：
Lin, Daniel
Quan, Wenying
Garretson, Marne
Chirikov, Viktor
Chen, Clara
Singh, Prianka
Davis, Catherine
Sugarman, Ryan
机构：
[1] Thomas Jefferson Univ Hosp, Philadelphia, PA USA
[2] OPEN Hlth, Bethesda, MD USA
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4044
引用
收藏
页数：1
相关论文
共 38 条
  • [1] A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of patients in CheckMate 649: Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC)
    Sugarman, Ryan
    Botteman, Marc
    Rusibamayila, Nifasha
    Nguyen, Hiep
    Lin, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [2] Q-TWiST analysis of nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC) in patients with PD-L1 CPS≥1 and CPS≥5: 4-year follow-up from CheckMate 649 (CM 649)
    Lin, D.
    Quan, W.
    Garretson, M.
    Chirikov, V. V.
    Chen, C.
    Singh, P.
    Davis, C.
    Sugarman, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S170 - S170
  • [3] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649
    Elimova, Elena
    Shitara, Kohei
    Moehler, Markus H.
    Ajani, Jaffer A.
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan S.
    Yamaguchi, Kensei
    Cleary, James M.
    Maya, Ricardo Elias Bruges
    Karamouzis, Michalis
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Tehfe, Mustapha
    Feeney, Kynan
    Wang, Rui
    Nathani, Raheel
    Janjigian, Yelena Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
    Shitara, Kohei
    Moehler, Markus H.
    Ajani, Jaffer A.
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan S.
    Yamaguchi, Kensei
    Cleary, James M.
    Elimova, Elena
    Maya, Ricardo Elias Bruges
    Karamouzis, Michalis
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Tehfe, Mustapha
    Feeney, Kynan
    Wang, Rui
    Nathani, Raheel
    Janjigian, Yelena Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 306 - 306
  • [5] Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC)
    Sugarman, Ryan
    Nunna, Sasikiran
    Betts, Keith A.
    Nie, Xiaoyu
    Nguyen, Hiep
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [6] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up
    Shen, Lin
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Rui-Hua
    Guo, Weijian
    Qin, Shukui
    Wang, Rui
    McCraith, Stephen
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 318 - 318
  • [7] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
    Moehler, M.
    Janjigian, Y. Y.
    Shitara, K.
    Garrido, M.
    Gallardo, C.
    Shen, L.
    Yamaguchi, K.
    Wyrwicz, L.
    Skoczylas, T.
    Bragagnoli, A.
    Liu, T.
    Tehfe, M.
    Elimova, E.
    Bruges, R.
    Cleary, J. M.
    Karamouzis, M.
    Soleymani, S.
    Lei, M.
    Amaya, Chanaga C.
    Ajani, J. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 114 - 115
  • [8] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
    Janjigian, Yelena Y.
    Shitara, Kohei
    Moehler, Markus H.
    Garrido, Marcelo
    Gallardo, Carlos
    Shen, Lin
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Bragagnoli, Arinilda Silva Campos
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Maya, Ricardo Elias Bruges
    Cleary, James M.
    Karamouzis, Michalis
    Soleymani, Samira
    Lei, Ming
    Amaya-Chanaga, Carlos
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
    Moehler, M.
    Shitara, K.
    Garrido, M.
    Salman, P.
    Shen, L.
    Wyrwicz, L.
    Yamaguchi, K.
    Skoczylas, T.
    Campos Bragagnoli, A.
    Liu, T.
    Schenker, M.
    Yanez, P.
    Tehfe, M.
    Poulart, V.
    Cullen, D.
    Lei, M.
    Kondo, K.
    Li, M.
    Ajani, J. A.
    Janjigian, Y. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1191 - S1191
  • [10] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
    Janjigian, Yelena Y.
    Shitara, Kohei
    Moehler, Markus H.
    Garrido, Marcelo
    Gallardo, Carlos
    Shen, Lin
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Bragagnoli, Arinilda Silva Campos
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Maya, Ricardo Elias Bruges
    Cleary, James M.
    Karamouzis, Michalis
    Soleymani, Samira
    Lei, Ming
    Amaya-Chanaga, Carlos
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 291 - 291
1234